Chronic Obstructive Pulmonary Disease: key endpoint results by drug
The key endpoints of Chronic Obstructive Pulmonary Disease trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Chronic Obstructive Pulmonary Disease page.
Moderate or severe exacerbations, annualised rate
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Aclidinium bromide | 0.4 | 0.6 | −0.1 | wk 52 · n 1791 | NCT01966107 Phase 4, primary |
| Benralizumab | 0.9 | 0.9 | ±0 | 100 mg · wk 56.14 · n 40 | NCT01227278 Phase 2, primary |
| dupilumab | 0.8 | 1.0 | −0.2 | 300 mg q2w · wk 52 · n 468 | NCT03930732 Phase 3, primary |
| fluticasone furoate/umeclidinium/vilanterol | 0.9 | 1.1 (FF/VI) | — | wk 52 · n 4145 | NCT02164513 Phase 3, primary |
| Mepolizumab | 1.4 | 1.7 | −0.3 | 100 mg · wk 52 · n 233 | NCT02105948 Phase 3, primary |
| Olodaterol | 0.6 | 0.7 | −0.1 | 10 mcg qd · wk 48 · n 234 | NCT00796653 Phase 3, secondary |
| Tiotropium bromide | 0.9 | 1.3 | −0.4 | 18μg · n 54 | NCT01663987 Phase 4, secondary |
Drugs checked with no result here: 12 trial running, 14 not reported, 9 not posted.
Trough FEV1, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Aclidinium bromide | 0.1 | -0.1 | +0.2 | 400/12 μg · wk 24 · n 262 | NCT03022097 Phase 3, primary |
| Aclidinium bromide/formoterol fumarate | 0.1 | -0.0 | +0.1 | 400/12 μg · wk 24 · n 335 | NCT01437397 Phase 3, primary |
| ensifentrine | -0.0 | -0.0 | ±0 | wk 24 · n 498 | NCT04542057 Phase 3, secondary |
| fluticasone furoate/umeclidinium/vilanterol | 0.1 | -0.0 (BUD/FOR) | — | 100/62.5/25 µg · wk 24 · n 836 | NCT02345161 Phase 3, primary |
| Olodaterol | 0.0 | -0.1 | +0.1 | 10 mcg qd · wk 24 · n 228 | NCT00796653 Phase 3, primary |
| Revefenacin | 0.1 | -0.1 | +0.2 | 175 mcg QD · wk 12.1 · n 105 | NCT05046795 Phase 3, primary |
| Tiotropium bromide | 0.1 | 0.1 (AB) | — | 400/12 μg · wk 24 · n 314 | NCT02796677 Phase 3, primary |
| Umeclidinium | 0.1 | -0.0 | +0.2 | 62.5 mcg · wk 24 · n 176 | NCT02184611 Phase 3, primary |
| Umeclidinium/Vilanterol | 0.2 | 0.1 (TIO) | — | 62.5/25 µg · wk 24 · n 400 | NCT01777334 Phase 3, primary |
Drugs checked with no result here: 10 trial running, 14 not reported, 9 not posted.
SGRQ total, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Aclidinium bromide | -8.7 | -4.7 | −4 | 400/12 μg · wk 24 · n 262 | NCT03022097 Phase 3, secondary |
| Aclidinium bromide/formoterol fumarate | -6.6 | -2.2 | −4.4 | 400/12 μg · wk 24 · n 335 | NCT01437397 Phase 3, secondary |
| astegolimab | 56.6 | 59.6 | −3 | wk 24 · n 42 | NCT03615040 Phase 2, secondary |
| dupilumab | -9.7 | -6.4 | −3.4 | 300 mg q2w · wk 52 · n 456 | NCT03930732 Phase 3, secondary |
| ensifentrine | -4.5 | -4.1 | −0.5 | wk 24 · n 489 | NCT04542057 Phase 3, secondary |
| fluticasone furoate/umeclidinium/vilanterol | -6.6 | -4.3 (BUD/FOR) | — | 100/62.5/25 µg · wk 24 · n 846 | NCT02345161 Phase 3, primary |
| Mepolizumab | -2.8 | -3 | +0.2 | 100 mg · wk 52 · n 226 | NCT02105948 Phase 3, secondary |
| Olodaterol | 37.1 | 42.0 | −4.9 | 5 μg + 5 μg · wk 12 · n 196 | NCT01964352 Phase 3, primary |
| Revefenacin | -4.8 | 0.2 | −5 | 175 mcg QD · wk 12.1 · n 110 | NCT05046795 Phase 3, secondary |
| Tiotropium bromide | -4.1 | -2.0 | −2.1 | wk 12 · n 315 | NCT00496470 Phase 4, secondary |
| tozorakimab | -9.2 | -8.3 | −0.9 | wk 12 · n 62 | NCT04631016 Phase 2, secondary |
| Umeclidinium | -6.2 | -2.1 | −4 | 62.5/25 mcg · wk 12 · n 212 | NCT02152605 Phase 3, primary |
Drugs checked with no result here: 11 trial running, 12 not reported, 7 not posted.
TDI focal score
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Aclidinium bromide | 2.9 | 2.1 | +0.8 | 400/12 μg · wk 24 · n 262 | NCT03022097 Phase 3, secondary |
| Aclidinium bromide/formoterol fumarate | 2.0 | 0.6 | +1.4 | 400/12 μg · wk 24 · n 335 | NCT01437397 Phase 3, secondary |
| ensifentrine | 1.9 | 0.8 | +1.1 | wk 24 · n 471 | NCT04535986 Phase 3, secondary |
| fluticasone furoate/umeclidinium/vilanterol | 2.3 | 1.7 (BUD/FOR) | — | 100/62.5/25 µg · wk 24 · n 839 | NCT02345161 Phase 3, secondary |
| Olodaterol | 1.5 | 1.1 | +0.4 | 10 mcg qd · wk 24 · n 220 | NCT00796653 Phase 3, primary |
| Umeclidinium | 2.5 | 1.6 | +0.9 | 62.5 mcg · wk 24 · n 176 | NCT02184611 Phase 3, secondary |
Drugs checked with no result here: 11 trial running, 15 not reported, 10 not posted.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 42 approved or late-stage drugs with a featured trial in Chronic Obstructive Pulmonary Disease were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.